$18.66
-0.025-0.13%
Últ. Act.: Oct 22, 3:57 PM
$18.60
-0.08-0.43%
Denali Therapeutics (DNLI) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.57 | $-0.71 | $-0.75 | $-0.76 |
| Actual | $-0.68 | $-0.69 | $-0.73 | $-0.74 |
| Surprise | -19.3% | +2.82% | +2.67% | +2.63% |
| Revenue | ||||
| Estimate | $2.0M | $3.8M | $9.0M | $6.2M |
| Actual | $3.6M | $0 | $0 | $0 |
| Surprise | +77.2% | -100.0% | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.43 | $-0.63 | $-0.54 | $-0.56 |
| Revenue | ||||
| Consensus | $20.8M | $24.8M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.68 | $-0.57 | -19.3 % |
| Q1 | May 7, 2026 | $-0.69 | $-0.71 | 2.82 % |
| Q4 | Feb 26, 2026 | $-0.73 | $-0.75 | 2.67 % |
| Q3 | Nov 6, 2025 | $-0.74 | $-0.76 | 2.63 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $3.60M | $2.03M | 77.2 % |
| Q1 | May 7, 2026 | $0 | $3.82M | -100.0 % |
| Q4 | Feb 26, 2026 | $0 | $8.99M | -100.0 % |
| Q3 | Nov 6, 2025 | $0 | $6.18M | -100.0 % |